SK Biopharmaceuticals Unlocks Potential

in Digital Healthcare at CES 2023

 

- SK Biopharmaceuticals showcases 5 wearable devices, including 2 CES Innovation Awards Honorees

- SK Group Chairman Tae-won Chey backs SK Biopharmaceuticals' vision for digital healthcare

- SK Biopharmaceuticals CEO Donghoon Lee holds on-site meetings for global partnerships

 

Las Vegas/Korea, Jan. 9, 2023 – SK Biopharmaceuticals, an innovative global pharmaceutical company, finished strong showcasing its innovative wearable devices for patients with epilepsy to both industry and public attendees at the CES 2023 in Las Vegas, Jan. 5-8.

 

The company made a debut at the world’s biggest and most influential tech show on Jan. 5, exhibiting five wearable devices, including "Zero GlassesTM" and "Zero WiredTM” that won the CES 2023 Innovation Awards. These devices under development are part of the so-called “Project ZeroTM,” aimed at optimizing SK Biopharmaceuticals’ digital healthcare ecosystem.

 

SK Group Chairman Tae-won Chey made a surprise visit to the company’s booth, trying on “Zero GlassesTM” and supporting SK Biopharmaceuticals’ digital transformation and healthcare that can help spur its competitiveness in the global pharmaceutical industry.

 

Also, SK Biopharmaceuticals CEO Donghoon Lee held a series of on-site executive meetings, including with Cala Health CEO Renee Ryan not only to explore new business opportunities but also to further boost strategic partnerships. SK Inc. and SK Biopharmaceuticals invested in Cala Health, a U.S. bioelectronic medicine leader, last year.

 

“Our debut at the CES 2023 with the five wearable devices is just a beginning of our digital journey that will take us to the next level in innovation,” said Mr. Donghoon Lee, the Chief Executive Officer of SK Biopharmaceuticals. “We will use both internal and external resources, further pursuing intrapreneurship and open innovation to become a technologically advanced global healthcare company in the near future.”

SK Group Chairman Tae-won Chey, right, visits SK Biopharmaceuticals' CES booth, and tries on "Zero GlassesTM" at the tech show, Las Vegas, Jan. 6, 2023. (SK Biopharmaceuticals)

 

SK Biopharmaceuticals CEO Donghoon Lee, right, shakes hands with Cala Health CEO Renee Ryan, left, ahead of a meeting at the CES 2023, Las Vegas, Jan. 6, 2023. (SK Biopharmaceuticals) 

 

About SK Biopharmaceuticals

SK Biopharmaceuticals and its U.S. subsidiary SK Life Science are global pharmaceutical companies focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS). The companies have a pipeline of eight new compounds in development for the treatment of CNS disorders, including epilepsy. Additionally, SK Biopharmaceuticals is focused on early research in oncology. For more information, visit SK Biopharmaceuticals’ website at www.skbp.com/eng and SK Life Science’s website at www.SKLifeScienceInc.com.

 

Media Inquiries

SK Biopharmaceuticals

H. Park, Head of Communications

Hyunkyung Cho, Deputy Communications Manager

skbp_comm@sk.com